Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.

Completed

Conditions studied: Migraine

In brief

This was a retrospective registry-based study utilizing data collected in association with clinical care of patients. All data was stored in electronic health records at Terveystalo data base, and no patients were contacted for the study.

Key facts

Study ID

NCT05375097

Run by

Novartis Pharmaceuticals

People needed

162

Starts

2020-07-03

Expected to finish

2021-05-14

Last updated by the study team

2022-07-01

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients on erenumab treatment ATC: N02CX07
• Diagnosis of migraine (ICD G43)
• Consented
• Occupational healthcare

You may not qualify if…

• None

Where it is running

• Novartis Investigative Site — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.